Sarepta Therapeutics’ (SRPT) “Outperform” Rating Reiterated at Wedbush
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a note issued to investors on Tuesday. They presently have a $66.00 price target on the stock. Wedbush’s target price points to a potential upside of 34.86% from the stock’s current price.
Several other brokerages have also recently commented on SRPT. Oppenheimer Holdings Inc. increased their price target on Sarepta Therapeutics from $60.00 to $76.00 in a research report on Monday. JMP Securities raised Sarepta Therapeutics to an “outperform” rating and increased their price target for the company from $10.00 to $60.00 in a research report on Monday. Cowen and Company raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $64.00 price target for the company in a research report on Tuesday. SunTrust Banks Inc. raised Sarepta Therapeutics from a “reduce” rating to a “neutral” rating in a research report on Wednesday, September 14th. Finally, Jefferies Group restated an “underperform” rating and issued a $7.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, September 15th. Two research analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $51.01.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 11.05% during mid-day trading on Tuesday, hitting $54.35. The stock had a trading volume of 13,499,373 shares. Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $56.80. The stock’s market capitalization is $2.60 billion. The stock has a 50 day moving average of $27.32 and a 200-day moving average of $21.07.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/sarepta-therapeutics-inc-srpt-receives-outperform-rating-from-wedbush.html
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the business earned ($0.87) earnings per share. On average, equities research analysts predict that Sarepta Therapeutics will post ($5.16) earnings per share for the current year.
In related news, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.90% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. American Century Companies Inc. bought a new position in shares of Sarepta Therapeutics during the second quarter valued at about $651,000. Eagle Asset Management Inc. bought a new position in shares of Sarepta Therapeutics during the second quarter valued at about $6,756,000. Amici Capital LLC bought a new position in shares of Sarepta Therapeutics during the first quarter valued at about $488,000. LGL Partners LLC raised its position in shares of Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock valued at $485,000 after buying an additional 1,000 shares in the last quarter. Finally, A.R.T. Advisors LLC bought a new position in shares of Sarepta Therapeutics during the first quarter valued at about $7,461,000. 72.09% of the stock is owned by institutional investors and hedge funds.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.